Rocket One Inc.
RKTONasdaq
$0.81
↓ -4.1%Jul 17 close · end-of-day
Price
1Y↓ -39.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.8M
Enterprise Value
$8.8M
P/E
—
P/S
—
P/B
3.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-280.8%
ROIC
-7980.9%
Debt / Equity
—
Net Cash
$4.0M
Return 1Y
-39.4%
Company profile
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy. HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the. treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases. HT-003 to treat inflammatory bowel diseases, as well as acne and psor
- CEO
- Robbie Knie
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- New York
- Website
- hoththerapeutics.com
Earnings
RKTO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.17↓ -37.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.3M | -$14.1M | -$11.1M | -$8.0M | -$8.2M | -$12.4M |
| Net income | -$7.2M | -$14.3M | -$11.4M | -$8.1M | -$8.2M | -$12.5M |
| Diluted EPS | — | -$16.02 | -$9.50 | -$2.38 | -$1.28 | -$0.90 |
| Operating cash flow | -$6.1M | -$12.1M | -$9.3M | -$8.4M | -$7.0M | -$9.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.7M | -$2.2M | -$2.1M | -$3.5M | -$2.2M | -$4.1M | -$2.6M | -$2.6M |
| Net income | -$1.7M | -$2.2M | -$2.1M | -$3.5M | -$2.2M | -$4.1M | -$2.7M | -$2.7M |
| Diluted EPS | -$0.25 | -$0.32 | -$0.22 | -$0.27 | -$0.17 | -$0.30 | -$0.16 | -$0.17 |
| Operating cash flow | -$1.6M | -$1.6M | -$2.0M | -$2.8M | -$2.4M | -$2.5M | -$2.2M | -$3.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-28 | Knie Robb· CEO and President | Tax withholding | 310,744 | $1.21 | $376,000.24 | filing |
| 2025-08-27 | Knie Robb· CEO and President | Award | 800,000 | $0.00 | $0.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.